Two convenient ways to get ARESTIN

Option 1:

Help your patients save with ARESTIN Rx Access

How ARESTIN Rx Access works:

process graphic

Commercially insured patients may be eligible for as low as a $0 copay*

Get Started

On average, 6 out of 10 patients qualify for prescription coverage through their medical prescription benefits¹
Increase patient access to a full-infection treatment^†

Questions? Call our dedicated service center: 1-855-684-7481.

*Please see Offer Restrictions and Eligibility Requirements on the Prescription Form.
†Full infection treatment refers to all clinically indicated sites in the treatment of chronic adult periodontitis.

Option 2:

Order ARESTIN to keep in stock at your office

Be sure to keep your office stocked with ARESTIN for:

Same-day treatment of as many indicated sites as needed after initial scaling and root planing (SRP)²
Use in the absence of prescription coverage
Maintenance appointments²

Order ARESTIN directly from our authorized distributors:

In the United States, contact Henry Schein:

logo henry shein

LOG IN/ REGISTER

In Canada, contact HANSAmed Limited:

logo hansamed

LOG IN/ REGISTER

WATCH THIS VIDEO

for tips on introducing ARESTIN Rx Access to your patients.

Download Library

Prescription Form
To see a sample form, click here.

REFERENCES: 1. Data on file. OraPharma. Bridgewater, NJ; 2011-2015. 2. ARESTIN^® (minocycline hydrochloride) Microspheres, 1 mg. Prescribing Information. OraPharma; Bridgewater, NJ.

For Students

For Faculty

INDICATION

ARESTIN^® (minocycline HCl) Microspheres, 1mg is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN^® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.

IMPORTANT SAFETY INFORMATION

ARESTIN is contraindicated in any patient who has a known sensitivity to minocycline or tetracyclines. Hypersensitivity reactions and hypersensitivity syndrome that included, but were not limited to anaphylaxis, anaphylactoid reaction, angioneurotic edema, urticaria, rash, eosinophilia, and one or more of the following: hepatitis, pneumonitis, nephritis, myocarditis, and pericarditis may be present. Swelling of the face, pruritus, fever and lymphadenopathy have been reported with the use of ARESTIN. Some of these reactions were serious. Post-marketing cases of anaphylaxis and serious skin reactions such as Stevens Johnson syndrome and erythema multiforme have been reported with oral minocycline, as well as acute photosensitivity reactions.
THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH, AND THEREFORE SHOULD NOT BE USED IN CHILDREN OR IN PREGNANT OR NURSING WOMEN.
Tetracyclines, including oral minocycline, have been associated with development of autoimmune syndromes including a lupus-like syndrome manifested by arthralgia, myalgia, rash, and swelling. Sporadic cases of serum sickness-like reaction have presented shortly after oral minocycline use, manifested by fever, rash, arthralgia, lymphadenopathy and malaise. In symptomatic patients, diagnostic tests should be performed and ARESTIN treatment discontinued.
The use of ARESTIN in an acutely abscessed periodontal pocket or for use in the regeneration of alveolar bone has not been studied.
The safety and effectiveness of ARESTIN has not been established in immunocompromised patients or in those with coexistent oral candidiasis. Use with caution if there is a predisposition to oral candidiasis.
In clinical trials, the most frequently reported nondental treatment-emergent adverse events were headache, infection, flu syndrome, and pain.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Click here for full Prescribing Information.